Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
In Reply: In response to Drs Ardizzoni and
Tiseo, we documented disease progression or treatment intolerability as the
reason for discontinuation of prior therapy in all patients. However, we did
not measure best overall response to chemotherapy given prior to enrollment.
Therefore, we do not know if response to prior chemotherapy predicts sensitivity
to gefitinib. However, we recorded the time from cancer diagnosis to the start
of gefitinib therapy. For the 194 patients with no radiographic response,
the median time from diagnosis to starting gefitinib was 19.8 months compared
with 18.6 months for the 22 patients who had a radiographic response while
receiving gefitinib. These data suggest that at least in terms of time from
diagnosis, the natural history of non–small cell lung cancer in gefitinib-sensitive
and gefitinib-resistant patients was comparable in our study.
Kris MG, Kay AC, Ochs JJ, Wolf MK. Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib—Reply. JAMA. 2004;291(13):1563. doi:10.1001/jama.291.13.1563-b